Research programme: ocular therapeutics - Genisphere

Drug Profile

Research programme: ocular therapeutics - Genisphere

Alternative Names: G8-3DNA-Dox; GL-249

Latest Information Update: 14 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genisphere
  • Class DNA; Immunoconjugates
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Postoperative inflammation

Most Recent Events

  • 09 Jun 2016 GL 249 is available for licensing as of 09 Jun 2016. http://www.genisphere.com/about-us
  • 01 May 2016 Preclinical trials in Postoperative Inflammation in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top